Granted Patent
B2
US 12,403,179 · App. 17/675,762 · Granted Sep 2, 2025
Release of growth factors at wound healing stages
Inventors:
Joshua Sakon (Fayetteville, AR); Robert Beitle (Fayetteville, AR); Hazim Aljewari (Fayetteville, AR); Osamu Matsushita (Okayama, JP); Stephanie Beitle (Fayetteville, AR)
Assignees:
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS; NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides collagen-binding agents that can be used to treat wounds, ischemic heart disease, and other conditions. The collagen-binding agents comprise a therapeutic agent, a protease cleavage site, and a collagen-binding domain. The present invention further provides pharmaceutical compositions and biomedical devices comprising the disclosed collagen-binding agents, as well as methods for treating a condition using the collagen-binding agents.
Claims (7)
1. A collagen-binding agent comprising SEQ ID NO:1.
2. A pharmaceutical composition comprising the collagen-binding agent of claim 1 and a pharmaceutically acceptable carrier.
3. A method of treating a condition, the method comprising:
administering the collagen-binding agent of claim 1 to a subject in an amount effective to treat the condition, wherein the condition is a wound.
4. The method of claim 3 , wherein the subject is a mammal.
5. A biomedical device comprising a coating that comprises the collagen-binding agent of claim 1 , wherein the biomedical device is a stent and wherein the coating further comprises a biodegradable polymer or a collagen.
6. A method of using the biomedical device of claim 5 to treat a condition, the method comprising: administering the device to a subject having the condition, wherein the condition is a wound.
Assignments (3)
CONFIRMATORY LICENSE
Recorded Jan 30, 2024
From: UNIVERSITY OF ARKANSAS AT FAYETTEVILLE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 066380/0275 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 6, 2022
From: MATSUSHITA, OSAMU
To: NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY
Reel/Frame 059844/0498 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 18, 2022
From: SAKON, JOSHUA; BEITLE, ROBERT; ALJEWARI, HAZIM; BEITLE, STEPHANIE
To: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
Reel/Frame 059052/0428 →
Continuity (2)
Provisional Application
63151023
· Feb 18, 2021
References Cited (400)
US 5914126A
· Li et al.
· 1999
[cited by applicant]
US 6077692A
· Ruben
· 2000
[cited by examiner]
US 6362163B1
· Gardella et al.
· 2002
[cited by applicant]
US 7167059B2
· Abraham et al.
· 2007
[cited by applicant]
US 7396664B2
· Daly
· 2008
[cited by applicant]
US 7465537B2
· Raney et al.
· 2008
[cited by applicant]
US 8030448B2
· Koide et al.
· 2011
[cited by applicant]
US 8450273B2
· Sakon et al.
· 2013
[cited by applicant]
US 8488203B2
· Higashyyama et al.
· 2013
[cited by applicant]
US 8617543B2
· Huang et al.
· 2013
[cited by applicant]
US 9062300B2
· Gensure et al.
· 2015
[cited by applicant]
US 9248164B2
· Uchida et al.
· 2016
[cited by applicant]
US 9354240B2
· Yamagata et al.
· 2016
[cited by applicant]
US 9526765B2
· Ponnapakkam et al.
· 2016
[cited by applicant]
US 9528099B2
· Gensure et al.
· 2016
[cited by applicant]
US 9579273B2
· Ponnapakkam et al.
· 2017
[cited by applicant]
US 9757435B2
· Herber
· 2017
[cited by applicant]
US 20020102709A1
· Ishikawa et al.
· 2002
[cited by applicant]
US 20040053368A1
· Ishikawa et al.
· 2004
[cited by applicant]
US 20040220094A1
· Skinner et al.
· 2004
[cited by applicant]
US 20050119183A1
· Wells et al.
· 2005
[cited by applicant]
US 20050124537A1
· Kostenuik et al.
· 2005
[cited by applicant]
US 20080108562A1
· Riviere et al.
· 2008
[cited by applicant]
US 20100159564A1
· Dwulet et al.
· 2010
[cited by applicant]
US 20180140742A1
· Uchida et al.
· 2018
[cited by applicant]
EP 0207751A1
· 1987
[cited by applicant]
JP 200258485
· 2002
[cited by applicant]
JP 2003284553
· 2003
[cited by applicant]
JP 2004500838
· 2004
[cited by applicant]
WO 2000006195
· 2000
[cited by applicant]
WO 2000049159
· 2000
[cited by applicant]
WO 2003052091
· 2003
[cited by applicant]
WO 2004071543
· 2004
[cited by applicant]
WO 2005082941
· 2005
[cited by applicant]
WO 2006072623
· 2006
[cited by applicant]
WO 2008067199
· 2008
[cited by applicant]
WO 2008124166
· 2008
[cited by applicant]
WO 2009014854
· 2009
[cited by applicant]
WO 2010087397
· 2010
[cited by applicant]
WO WO2010091251A2
· 2010
[cited by examiner]
WO 2011142425
· 2011
[cited by applicant]
WO 2012124338
· 2012
[cited by applicant]
WO 2012157339
· 2012
[cited by applicant]
WO 2016060252
· 2016
[cited by applicant]
WO 2016142146
· 2016
[cited by applicant]
WO 2017216620
· 2017
[cited by applicant]
WO 2019113123
· 2019
[cited by applicant]
WO 2019173829
· 2019
[cited by applicant]
WO WO2020068261A1
· 2020
[cited by examiner]
Vartak et al. Matrix metalloproteases: Underutilized targets for drug delivery. J Drug Target. Jan. 2007 ; 15(1): 1-20 (Year: 2007 ).
[cited by examiner]
Schmitt, C.P. et al., “Intermittent administration of parathyroid hormone (1-37) improves growth and bone mineral density in uremic rats,” Kidney Int. (2000) 57(4):1484-92.
[cited by applicant]
Schmitt, C.P. et al., “Structural organization and biological relevance of oscillatory parathyroid hormone secretion,” Pediatr Nephrol. (2005) 20(3):346-51. Epub Feb. 8, 2005.
[cited by applicant]
Schwartz, R.S., et al., Drug-eluting stents in preclinical studies: updated consensus recommendations for preclinical evaluation. Circ Cardiovasc Interv, 2008. 1(2): p. 143-53.
[cited by applicant]
Seeman, E. et al., “Reconstructing the skeleton with intermittent parathyroid hormone,” Trends Endocrinol Metab. (2001) 12(7):281-3.
[cited by applicant]
Sekiguchi, H. et al., “Acceleration of bone formation during fracture healing by poly(pro-hyp-gly)10 and basic fibroblast growth factor containing polycystic kidney disease and collagen-binding domains from Clostridium …
[cited by applicant]
Sekiguchi, H., et al. “Basic fibroblast growth factor fused with tandem collagen-binding domains from Clostridium histolyticum collagenase CoIG increases bone formation.” BioMed research international 2018 (2018).
[cited by applicant]
Sheikh, F., et al., Overexpression of FGF-2 increases cardiac myocyte viability after injury in isolated mouse hearts. Am J Physiol Heart Circ Physiol, 2001. 280(3): p. H1039-50.
[cited by applicant]
Shen, V. et al., “Skeletal effects of parathyroid hormone infusion in ovariectomized rats with or without estrogen repletion,” J Bone Miner Res. (2000) 15(4):740-6.
[cited by applicant]
Shimizu, N. et al., “Novel parathyroid hormone (PTH) antagonists that bind to the juxtamembrane portion of the PTH/PTH-related protein receptor,” J Biol Chem (2005) 280(3):1797-1807.
[cited by applicant]
Shin, H., et al. Efficacy of Interventions for Prevention of Chemotherapy-Induced Alopecia: A systematic review and meta-analysis. International Journal of Cancer. 2015. 136: E442-E454.
[cited by applicant]
Shinoda, Y. et al., “Mechanisms underlying catabolic and anabolic functions of parathyroid hormone on bone by combination of culture systems of mouse cells,” J. of Cellular Biology (2010) 109(4):755-63.
[cited by applicant]
Sides, C. R., et al.(2012). “Probing the 3-D Structure, Dynamics, and Stability of Bacterial Collagenase Collagen Binding Domain (apo- versus holo-) by Limited Proteolysis MALDI-TOF MS.” Journal of the American Society …
[cited by applicant]
Silver, J. et al., “Harnessing the parathyroids to create stronger bones,” Curr Opin Nephrol Hypertens. (2004) 13(4):471-6.
[cited by applicant]
Silverberg, S.J.et al., “Skeletal disease in primary hyperparathyroidism,” J Bone Miner Res., (1989) 4(3):283-91.
[cited by applicant]
Skripitz, R. et al., “Parathyroid hormone—a drug for orthopedic surgery?,” Acta Orthop Scand. (2004) 75(6):654-62.
[cited by applicant]
Skripitz, R. et al., “Stimulation of implant fixation by parathyroid hormone (1-34)—A histomorphometric comparison of PMMA cement and stainless steel,” J Orthop Res. (2005) 23(6):1266-70. Epub Jun. 16, 2005.
[cited by applicant]
Smajilovic, S. et al., “Effect of intermittent versus continuous parathyroid hormone in the cardiovascular system of rats,” Open Cardiovasc. Med. J. (2010) 4:110-6.
[cited by applicant]
Spadaccio, C., et al., Drug releasing systems in cardiovascular tissue engineering. J Cell Mol Med, 2009. 13(3): p. 422-39.
[cited by applicant]
Spiriti, J. et al (2010). “Mechanism of the calcium-induced trans-cis isomerization of a non-prolyl peptide bond in Clostridium histolyticum collagenase.” Biochemistry 49(25): 5314-5320.
[cited by applicant]
Stewart, A.F., “PTHrP(1-36) as a skeletal anabolic agent for the treatment of osteoporosis,” Bone (1996) 19(4):303-306.
[cited by applicant]
Stracke, S. et al., “Long-term outcome after total parathyroidectomy for the management of secondary hyperparathyroidism,” Nephron Clin Pract. (2009) 111(2):c102-9. Epub Jan. 13, 2009.
[cited by applicant]
Stratford, R., Jr., et al.(2014). “Pharmacokinetics in rats of a long-acting human parathyroid hormone-collagen binding domain peptide construct.” J Pharm Sci 103(2): 768-775.
[cited by applicant]
Strewler, G.J., “Local and systemic control of the osteoblast,” J. of Clin. Invest. (2001) 107:271-272.
[cited by applicant]
Suttamanatwong, S. et al., “Regulation of matrix Gla protein by parathyroid hormone in MC3T3-E1 osteoblast-like cells involves protein kinase A and extracellular signal-regulated kinase pathways,” J Cell Biochem. (2007)…
[cited by applicant]
Suttamanatwong, S. et al., “Sp proteins and Runx2 mediate regulation of matrix gla protein (MGP) expression by parathyroid hormone,” J Cell Biochem. (2009) 107(2):284-92.
[cited by applicant]
Suzuki, A. et al., “PTH/cAMP/PKA signaling facilitates canonical Wnt signaling via inactivation of glycogen synthase kinase-3beta in osteoblastic Saos-2 cells,” J Cell Biochem. (2008) 104(1):304-17.
[cited by applicant]
Swarthout, J.T. et al., “Parathyroid hormone-dependent signaling pathways regulating genes in bone cells,” Gene (2002) 282(1-2):1-17.
[cited by applicant]
Swarthout, J.T. et al., “Stimulation of extracellular signal-regulated kinases and proliferation in rat osteoblastic cells by parathyroid hormone is protein kinase C-dependent,” J Biol Chem. (2001) 276(10):7586-92. Epub…
[cited by applicant]
Takada, H. et al., “Response of parathyroid hormone to anaerobic exercise in adolescent female athletes,” Acta Paediatr Jpn. (1998) 40(1):73-7.
[cited by applicant]
Takasu, H. et al., “Dual signaling and ligand selectivity of the human PTH/PTHrP receptor,” J Bone Miner Res. (1999) 14(1):11-20.
[cited by applicant]
Talmage, R.V. et al., “Calcium homeostasis: reassessment of the actions of parathyroid hormone,” Gen Comp Endocrinol. (2008) 156(1):1-8. Epub Nov. 12, 2007.
[cited by applicant]
Tam, C.S. et al., “Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration,” Endocrinology (1982) 110(2):506-12.
[cited by applicant]
Tawfeek, H. et al., “Disruption of PTH receptor 1 in T cells protects against PTH-induced bone loss,” PLoS (2010) 5(8):e12290.
[cited by applicant]
Ten Dijke, P. et al., “Characterization of type I receptors for transforming growth factor-β and Activin,” Science (1994) 264:101-104.
[cited by applicant]
Ten Dijke, P. et al., “Identification of type I receptors for osteogenic Protein-1 and bone morphogenetic Protein-4,” J. of Biological Chem. (1994) 269(25):16985-16988.
[cited by applicant]
Tokumoto, M. et al., “Parathyroid cell growth in patients with advanced secondary hyperparathyroidism: vitamin D receptor, calcium sensing receptor, and cell cycle regulating factors,” Ther Apher Dial. (2005) 9(Suppl 1)…
[cited by applicant]
Tollin, S.R. et al., “Serial changes in bone mineral density and bone turnover after correction of secondary hyperparathyroidism in a patient with pseudohypoparathyroidism type lb,” J Bone Miner Res. (2000) 15(7):1412-6.
[cited by applicant]
Toyoshima, T. et al., “Collagen-binding domain of a Clostridium histolyticum collagenase exhibits a broad substrate spectrum both in vitro and in vivo,” Connective Tissue Research (2001) 42(4):281-290.
[cited by applicant]
Uchida K, et al: Acceleration of periosteal bone formation by human basic fibroblast growth factor containing a collagen-binding domain from Clostridium histolyticum collagenase. J Biomed Mater Res A 2014;102:1737-1743.
[cited by applicant]
Uchida, K. et al. “Enhancement of periosteal bone formation by basic fibroblast-derived growth factor containing polycystic kidney disease and collagen-binding domains from Clostridium histolyticum collagenase” J. Tissu…
[cited by applicant]
Ueno M, et al: Influence of internal fixator stiffness on murine fracture healing: two types of fracture healing lead to two distinct cellular events and FGF-2 expressions. Exp Anim 2011;60:79-87.
[cited by applicant]
Ueno, M., et al (2014). “Acceleration of bone union after structural bone grafts with a collagen-binding basic fibroblast growth factor anchored-collagen sheet for critical-size bone defects.” Biomed Mater 9(3): 035014.
[cited by applicant]
United States Patent Office Action for U.S. Appl. No. 12/594,547 dated Aug. 6, 2012 (12 pages).
[cited by applicant]
United States Patent Office Action for U.S. Appl. No. 14/365,226 dated Nov. 24, 2015 (8 pages).
[cited by applicant]
United States Patent Office Action for U.S. Appl. No. 14/365,226 dated Jun. 10, 2016 (9 pages).
[cited by applicant]
United States Patent Office Action for U.S. Appl. No. 14/378,067 dated Feb. 17, 2016 (16 pages).
[cited by applicant]
United States Patent Office Action for U.S. Appl. No. 15/407,589 dated Jun. 26, 2018 (44 pages).
[cited by applicant]
United States Patent Office Action for U.S. Appl. No. 15/407,589 dated Jun. 26, 2019 (7 pages).
[cited by applicant]
Uzawa, T. et al., “Comparison of the effects of intermittent and continuous administration of human parathyroid hormone(1-34) on rat bone,” Bone (1995) 16(4):477-84.
[cited by applicant]
Vanstone, M.B. et al., “Rapid correction of bone mass after parathyroidectomy in an adolescent with primary hyperparathyroidism,” J. Clin. Endocrinol. Metab. (2011) 96(2): E347-50. Epub Nov. 24, 2010.
[cited by applicant]
Davis, J.E., A. Alghanmi, R. K. Gundampati, S.Jayanthi, E. Fields, M. Armstrong, V. Weidling, V. Shah, S. Agrawal, B. P.Koppolu, D. A. Zaharoff, and S. K. Thallapuranam (2018) Probing the role of proline-135 on the stru…
[cited by applicant]
Davis, J.E., R. K. Gundampati, S. Jayanthi, J. Anderson, A. Pickhardt, B.P. Koppolu, D.A. Zaharoff, and S. K. Thallapuranam (2018) Effect of extension of the heparin binding pocket on the structure, stability, and cell …
[cited by applicant]
Deal, C., “The use of intermittent human parathyroid hormone as a treatment for osteoporosis,” Curr Rheumatol Rep. (2004) 6(1): 49-58.
[cited by applicant]
Demiralp, B. et al., “Anabolic actions of parathyroid hormone during bone growth are dependent on c-fos,” Endocrinology (2002) 143(10):4038-47.
[cited by applicant]
Derner, R. et al., “The bone morphogenic protein,” Clin. Podiatr. Med. Surg. (2005) 22(4):607-618.
[cited by applicant]
Dobnig, H. et al., “The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats,” Endocrinology (1997) 138(11):4607-12.
[cited by applicant]
Drake, M.T. et al., “Parathyroid hormone increases the expression of receptors for epidermal growth factor in UMR 106-01 cells,” Endocrinology (1994) 134(4):1733-7.
[cited by applicant]
Eckhard, U. et al.(2011). “Polycystic kidney disease-like domains of clostridial collagenases and their role in collagen recruitment.” Biol Chem 392(11): 1039-1045.
[cited by applicant]
Eckhard, U., et al.(2011). “Structure of collagenase G reveals a chew-and-digest mechanism of bacterial collagenolysis.” Nat Struct Mol Biol 18(10): 1109-1114. Published online Sep. 25, 2011. Final edited version publis…
[cited by applicant]
Endo, K. et al., “1,25-dihydroxyvitamin D3 as well as its analogue OCT lower blood calcium through inhibition of bone resorption in hypercalcemic rats with continuous parathyroid hormone-related peptide infusion,” J Bon…
[cited by applicant]
Etoh, M. et al., “Repetition of continuous PTH treatments followed by periodic withdrawals exerts anabolic effects on rat bone,” J Bone Miner Metab. (2010) 28(6):641-649.
[cited by applicant]
Extended European Search Report for Application No. 08742686.2 dated Aug. 4, 2010 (8 pages).
[cited by applicant]
Extended European Search Report for Application No. 12857691.5 dated Feb. 8, 2016 (16 pages).
[cited by applicant]
Farhanigan, M.E., et al. Treatment of Alopecia Areata in the United States: A Retrospective Cross-Sectional Study. J Drugs Dermatology. 2015 14(9):1012-4.
[cited by applicant]
Fitzpatrick, L.A. et al., “Acute primary hyperparathyroidism,” Am J Med. (1987) 82(2):275-82.
[cited by applicant]
Fleming, A. et al., “High-throughput in vivo screening for bone anabolic compounds with zebrafish,” J Biomol Screen. (2005) 10(8):823-31. Epub Oct. 18, 2005.
[cited by applicant]
Fouda, M.A., “Primary hyperparathyroidism: King Khalid University Hospital Experience,” Ann Saudi Med. (1999) 19 (2):110-5.
[cited by applicant]
Fox, J. et al., “Effects of daily treatment with parathyroid hormone 1-84 for 16 months on density, architecture and biomechanical properties of cortical bone in adult ovariectomized rhesus monkeys,” Bone (2007) 41(3):3…
[cited by applicant]
Fraher, L.J. et al., “Comparison of the biochemical responses to human parathyroid hormone-(1-31)NH2 and hPTH-(1-34) in healthy humans,” J Clin Endocrinol Metab. (1999) 84(8):2739-43.
[cited by applicant]
Franzen, P. et al., “Cloning of a TGFβ type I receptor that forms a heteromeric complex with the TGFβ type II receptor,” Cell (1993) 75:681-692.
[cited by applicant]
Frolik, C.A. et al., “Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure,” Bone (2003) 33(3):372-379.
[cited by applicant]
Fruchtl M, Sakon J, Beitle R. Expression of a collagen-binding domain fusion protein: effect of amino acid supplementation, inducer type, and culture conditions. Biotechnol Prog. Mar.-Apr. 2015;31(2):503-9. PubMed PMID:…
[cited by applicant]
Fruchtl, M., J. Sakon and R. Beitle (2016). “Alternate carbohydrate and nontraditional inducer leads to increased productivity of a collagen binding domain fusion protein via fed-batch fermentation.” Journal of Biotechn…
[cited by applicant]
Fuentes, J. et al., “A PTH/PTHrP receptor antagonist blocks the hypercalcemic response to estradiol-17beta,” Am. J. Physiol. Regul. Integr. Comp. Physiol. (2007) 293(2):R956-960.
[cited by applicant]
Wong, V.W., et al., Surgical approaches to create murine models of human wound healing. J Biomed Biotechnol, 2011. 2011: p. 969618.
[cited by applicant]
Fujimaki, H., et al (2016). “Oriented collagen tubes combined with basic fibroblast growth factor promote peripheral nerve regeneration in a 15 mm sciatic nerve defect rat model.” J Biomed Mater Res A.
[cited by applicant]
Fujita, T., “Parathyroid hormone in the treatment of osteoporosis,” BioDrugs (2001) 15(11):721-728.
[cited by applicant]
Fukayama, S. et al., “New insights into interactions between the human PTH/PTHrP receptor and agonist/antagonist binding,” Am. J. Physiol. Endocrinol. Metab. (1998) 274:297-303.
[cited by applicant]
Gao, Y. et al., “T cells potentiate PTH-induced cortical bone loss through CD40L signaling,” Cell Metab. (2008) 8(2):132-45.
[cited by applicant]
Gardella, T.J. et al., “Converting Parathyroid Hormone-related Peptide (PTHrP) into a Potent PTH-2 Receptor Agonist,” J. of Biological Chemistry, (1996) 271(33):19888-19893.
[cited by applicant]
Gaston, R. G., et al.(2015). “The Efficacy and Safety of Concurrent Collagenase Clostridium Histolyticum Injections for 2 Dupuytren Contractures in the Same Hand: A Prospective, Multicenter Study.” J Hand Surg Am 40(10)…
[cited by applicant]
Gensure, R.C. et al., “Parathyroid hormone and parathyroid hormone-related peptide, and their receptors,” Biochem Biophys Res Commun. (2005) 328(3):666-78.
[cited by applicant]
Gensure, R.C. et al., “Parathyroid hormone without parathyroid glands,” Endocrinology (2005) 146(2):544-546.
[cited by applicant]
Gensure, R.C. et al., “Parathyroid hormone-related peptide and the hair cycle—is it the agonists or the antagonists that cause hair growth?” (2014) Experimental Dermatology, 23(12):865-867.
[cited by applicant]
Gevers, E.F. et al., “Bone marrow adipocytes: a neglected target tissue for growth hormone,” Endocrinology (2002) 143(10):4065-73.
[cited by applicant]
Goltzman, D., “Studies on the mechanisms of the skeletal anabolic action of endogenous and exogenous parathyroid hormone,” Arch Biochem Biophys. (2008) 473(2):218-24. Epub Mar. 10, 2008.
[cited by applicant]
Gopalakrishnan, R. et al., “Role of matrix Gla protein in parathyroid hormone inhibition of osteoblast mineralization,” Cells Tissues Organs (2005) 181(3-4):166-75.
[cited by applicant]
Gosavi, A. et al., “An unusual presentation of parathyroid adenoma—a case report,” Indian J Pathol Microbiol. (2005) 48(2):208-10.
[cited by applicant]
Gu, W.X. et al., “Mutual up-regulation of thyroid hormone and parathyroid hormone receptors in rat osteoblastic osteosarcoma 17/2.8 cells,” Endocrinology (2001) 142(1):157-64.
[cited by applicant]
Guise, T.A., “Parathyroid hormone-related protein and bone metastases,” Cancer (1997) 80(8 Supp):1572-1580.
[cited by applicant]
Hall, A.K. et al., “The effects of parathyroid hormone on osteoblast-like cells from embryonic chick calvaria,” Acta Endocrinol (Copenh). (1985) 108(2):217-23.
[cited by applicant]
Han X, et al: Accelerated postero-lateral spinal fusion by collagen scaffolds modified with engineered collagen-binding human bone morphogenetic protein-2 in rats. PLoS One 2014;9:e98480.
[cited by applicant]
Han, B. et al., “Collagen-targeted BMP3 fusion proteins arrayed on collagen matrices or porous ceramics impregnated with Type I collagen enhance osteogenesis in a rat cranial defect model,” J Orthopaedic Research (2002)…
[cited by applicant]
Han, B. et al., “Refolding of a recombinant collagen-targeted TGF-beta2 fusion protein expressed in
[cited by applicant]
Hashimoto, et al., Sequential treatment with intermittent low-dose human parathyroid hormone (1-34) and bisphosphonate enhances large-size skeletal reconstruction by vascularized bone transplantation. Calcif. Tissue Int…
[cited by applicant]
Hausenloy, D.J. and D.M. Yellon, New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res, 2004. 61(3): p. 448-60.
[cited by applicant]
Hausenloy, D.J. and D.M. Yellon, Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev, 2007. 12(3-4): p. 217-34.
[cited by applicant]
Headley, C.M., “Hungry bone syndrome following parathyroidectomy,” Anna J., (1998) 25(3):283-9; quiz 290-1.
[cited by applicant]
Heath, H., 3rd, “Clinical spectrum of primary hyperparathyroidism: evolution with changes in medical practice and technology,” J Bone Miner Res. (1991) 6(Suppl 2):S63-70; discussion S83-4.
[cited by applicant]
Henderson, M.A. et al., “Parathyroid hormone-related protein localization in breast cancers predict improved prognosis,” Cancer Res. (2006) 66(4):2250-2256.
[cited by applicant]
Orloff, J.J. et al., Parathyroid hormone-related protein as a prohormone: posttranslational processing and receptor interactions. Endocrine Rev (1994) 15:40-60.
[cited by applicant]
Owens, R.J. et al., “Mapping the collagen-binding site of human fibronectin by expression in
[cited by applicant]
Padua, R.R., et al., FGF-2-induced negative inotropism and cardioprotection are inhibited by chelerythrine: involvement of sarcolemmal calcium-independent protein kinase C. J Mol Cell Cardiol, 1998. 30(12): p. 2695-709.
[cited by applicant]
Paillard, M. et al., “Determinants of parathormone secretion in primary hyperparathyroidism,” Horm Res. (1989) 32(1-3):89-92.
[cited by applicant]
Palmen, M., et al., Fibroblast growth factor-1 improves cardiac functional recovery and enhances cell survival after ischemia and reperfusion: a fibroblast growth factor receptor, protein kinase C, and tyrosine kinase d…
[cited by applicant]
Parfitt, A.M. et al., “Hypercalcemia due to constitutive activity of the parathyroid hormone (PTH)/PTH-related peptide receptor: comparison with primary hyperparathyroidism,” J Clin Endocrinol Metab. (1996) 81(10):3584-…
[cited by applicant]
Parfitt, A.M., “The actions of parathyroid hormone on bone: relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone disease. Part IV of IV parts: The state of the bones in uremic hyperaparathyr…
[cited by applicant]
Partial Supplementary European Search Report dated Oct. 1, 2015 (7 pages).
[cited by applicant]
Perbellini, F., et al., Investigation of cardiac fibroblasts using myocardial slices. Cardiovasc Res, 2018. 114(1): p. 77-89.
[cited by applicant]
Peters, E.M.J. et al., “A new strategy for modulating chemotherapy-induced alopecia, using PTH/PTHrP receptor agonist and antagonist,” J Invest Dermatol (2001) 117(2):173-178.
[cited by applicant]
Pettway, et al., “Anabolic actions of PTH (1-34): Use of a novel tissue engineering model to investigate temporal effects on bone,” Bone (2005) 36(6):959-970.
[cited by applicant]
Phatharajaree, W., A. Phrommintikul, and N. Chattipakorn, Matrix metalloproteinases and myocardial infarction. Can J Cardiol, 2007. 23(9): p. 727-33.
[cited by applicant]
Phelps, E. et al., “Parathyroid hormone induces receptor activity modifying protein-3 (RAMP3) expression primarily via 3′,5′-cyclic adenosine monophosphate signaling in osteoblasts,” Calcif Tissue Int. (2005) 77(2):96-1…
[cited by applicant]
Philominathan et al., “Bacterial collagen-binding domain targets undertwisted regions of collagen,” Protein Sci. (2012) 21(10):1554-65.
[cited by applicant]
Philominathan et al., “Unidirectional binding of Clostridial Colleagenase to Triple Helical Substrates,” Journal of Biological Chemistry (2009) 284(16):10868-10876.
[cited by applicant]
Philominathan, S. T., et al.(2009). “Ca2+-induced linker transformation leads to a compact and rigid collagen-binding domain of Clostridium histolyticum collagenase.” FEBS J 276(13): 3589-3601.
[cited by applicant]
Pirih, F.Q. et al., “Parathyroid hormone induces the NR4A family of nuclear orphan receptors in vivo,” Biochem Biophys Res Commun. (2005) 332(2):494-503.
[cited by applicant]
Podbesek, R. et al., “Effects of two treatment regimes with synthetic human parathyroid hormone fragment on bone formation and the tissue balance of trabecular bone in greyhounds,” Endocrinology (1983) 112(3):1000-6.
[cited by applicant]
Ponnapakkam T, Katikaneni R, Sakon J, Stratford R, Gensure RC. Treating osteoporosis by targeting parathyroid hormone to bone. Drug Discov Today. Mar. 2014; 19(3):204-8. PubMed PMID: 23932952; PubMed Central PMCID: PMC3…
[cited by applicant]
Ponnapakkam, T. et al., “A fusion protein of parathyroid hormone (PTH) and a collagen binding domain shows superior efficacy and longer duration of action compared to PTH(1-34) as an anabolic bone agent in normal female…
[cited by applicant]
Ponnapakkam, T. et al., “A Single Injection of the Anabolic Bone Agent, Parathyroid Hormone-Collagen Binding Domain (PTH-CBD), Results in Sustained Increases in Bone Mineral Density for up to 12 Months in Normal Female …
[cited by applicant]
Ponnapakkam, T., et al.(2011). “Prevention of chemotherapy-induced osteoporosis by cyclophosphamide with a long-acting form of parathyroid hormone.” J Endocrinol Invest 34(11): e392-397.
[cited by applicant]
Ponnapakkam, T., et al., “Monthly administration of a novel PTH-collagen binding domain fusion protein is anabolic in mice,” Calcif Tissue Int.2011;88:511-520.
[cited by applicant]
Poole, K.E. et al., “Parathyroid hormone—a bone anabolic and catabolic agent,” Curr Opin Pharmacol. (2005) 5(6):612-7. Epub Sep. 21, 2005.
[cited by applicant]
Potter, L.K. et al., “Response to continuous and pulsatile PTH dosing: a mathematical model for parathyroid hormone receptor kinetics,” Bone (2005) 37(2):159-169.
[cited by applicant]
Potts, J.T., “Parathyroid hormone: past and present,” J Endocronology (2005) 187:311-325.
[cited by applicant]
Qin, L. et al., “Parathyroid hormone: a double-edged sword for bone metabolism,” Trends Endocrinol Metab. (2004) 15(2):60-5.
[cited by applicant]
Ragab, D., D.M. Abdallah, and H.S. El-Abhar, Cilostazol renoprotective effect: modulation of PPAR-gamma, NGAL, KIM-1 and IL-18 underlies its novel effect in a model of ischemia-reperfusion. PLoS One, 2014. 9(5): p. e953…
[cited by applicant]
Rattanakul, C. et al., “Modeling of bone formation and resorption mediated by parathyroid hormone: response to estrogen/PTH therapy” Biosystems (2003) 70(1):55-72.
[cited by applicant]
Reboucas, J.S., N.S. Santos-Magalhaes, and F.R. Formiga, Cardiac Regeneration using Growth Factors: Advances and Challenges. Arq Bras Cardiol, 2016. 107(3): p. 271-275.
[cited by applicant]
Restriction Requirement for U.S. Appl. No. 14/365,226 dated Jun. 22, 2015 (8 pages).
[cited by applicant]
Restriction Requirement for U.S. Appl. No. 14/378,067 dated Oct. 23, 2015 (9 pages).
[cited by applicant]
Restriction requirement for U.S. Appl. No. 14/743,629 dated Apr. 20, 2016 (8 pages).
[cited by applicant]
Restriction requirement for U.S. Appl. No. 15/407,589 dated Jan. 8, 2018 (5 pages).
[cited by applicant]
Richardson, M.L. et al., “Bone mineral changes in primary hyperparathyroidism,” Skeletal Radiol. (1986) 15(2):85-95.
[cited by applicant]
Rickard, D.J. et al., “Intermittent treatment with parathyroid hormone (PTH) as well as a non-peptide small molecule agonist of the PTH1 receptor inhibits adipocyte differentiation in human bone marrow stromal cells,” B…
[cited by applicant]
Rixon, R.H. et al., “Parathyroid hormone fragments may stimulate bone growth in ovariectomized rats by activating adenylyl cyclase,” J Bone Miner Res. (1994) 9(8):1179-89.
[cited by applicant]
Robinson, J.A. et al., “Identification of a PTH regulated gene selectively induced in vivo during PTH-mediated bone formation,” J Cell Biochem. (2006) 98(5):1203-20.
[cited by applicant]
Rosen, C.J., “The cellular and clinical parameters of anabolic therapy for osteoporosis,” Crit Rev Eukaryot Gene Expr. (2003) 13(1):25-38.
[cited by applicant]
Rubin, M. et al., “The anabolic effects of parathyroid hormone therapy,” Osteoporosis International (2002) 13(4):267-277.
[cited by applicant]
Rubin, M.R. et al., “The anabolic effects of parathyroid hormone therapy,” Clin Geriatr Med. (2003) 19(2):415-32.
[cited by applicant]
Rubin, M.R. et al., “The potential of parathyroid hormone as a therapy for osteoporosis,” Int J Fertil Womens Med. (2002) 47(3):103-15.
[cited by applicant]
Safer, J.D. et al., “A topical parathyroid hormone/parathyroid hormone-related peptide receptor antagonist stimulates hair growth in mice,” Endocrinology (2007)148:1167-1170.
[cited by applicant]
Saito W, et al: Acceleration of bone formation during fracture healing by injectable collagen powder and human basic fibroblast growth factor containing a collagen-binding domain from Clostridium histolyticum collagenas…
[cited by applicant]
Saito W, et al: Acceleration of callus formation during fracture healing using basic fibroblast growth factor-kidney disease domain-collagen-binding domain fusion protein combined with allogenic demineralized bone powde…
[cited by applicant]
Sakon, Joshua (2020) 12P Presentation, Preventing Heart Failure with Site-specific Growth Factor.
[cited by applicant]
Schaefer, F., “Pulsatile parathyroid hormone secretion in health and disease,” Novartis Found Symp. (2000) 227:225-39; discussion 239-43.
[cited by applicant]
Schilli, M.B. et al., “Control of hair growth with parathyroid hormone (7-34),” J Invest Dermatol (1997) 108:928-932.
[cited by applicant]
Schluter, K.-D. et al., “A N-terminal PTHrP peptide fragment void of a PTH/PTHrP-receptor binding domain activates cardiac ETA receptors,” British Journal of Pharmacology (2001) 132:427-432.
[cited by applicant]
Schluter, K.-D. et al., “Stem cell mobilization versus stem cell homing: potential role for parathyroid hormone?” Cardiovasc Res. (2008) 77(4):612-613.
[cited by applicant]
Abdelhadi, M. et al., “Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism,” J Clin Endocrinol Metab. (1998) 83(11):3845-51.
[cited by applicant]
Abe, Y. et al., “Enhancement of graft bone healing by intermittent administration of human parathyroid hormone (1-34) in a rat spinal arthrodesis model,” Bone (2007) 41(5):775-785.
[cited by applicant]
Abraham, M. et al., “Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-Benzoyl-TN14003,” Stem Cells (2007) 25:2158-2166.
[cited by applicant]
Abshirini, H. et al., “Pathologic fractures: a neglected clinical feature of parathyroid adenoma,” Case (2010) p. 357029. Epub Nov. 29, 2010.
[cited by applicant]
Akimoto, M. et al., “Effects of CB-VEGF-A injection in rat flap models for improved survival,” (2013) Plast. Reconstr. Surg. 131(4):717-725.
[cited by applicant]
Aleksyniene, R. et al., “Parathyroid hormone—possible future drug for orthopedic surgery,” Medicina (Kaunas) (2004) 40(9):842-9.
[cited by applicant]
Andrade, M.C., et al., “Bone mineral density and bone histomorphometry in children on long-term dialysis, ” Pediatr Nephrol. (2007) 22(10):1767-72. Epub Aug. 7, 2007.
[cited by applicant]
Andrades, J.A. et al., “A recombinant human TGF-beta1 fusion protein with collagen-binding domain promotes migration, growth, and differentiation of bone marrow mesenchymal cells,” Exp. Cell Res. (1999) 250(2):485-498.
[cited by applicant]
Arunkumar, A. I., S. K. Thallapuranam, K. M. Kathir, S. Srisailam, H. M. Wang, P. S. T. Leena, Y. H. Chi, C. H. Wu, R. T. Wu, I. M. Chiu and C. Yu. Oligomerization of acidic fibroblast growth factor is not a prerequisit…
[cited by applicant]
Balachandran K, Alford PW, Wylie-Sears J, Goss JA, Grosberg A, Aikawa E, Bischoff J, Levine RA, Parker KK. Cyclic Strain Induces Dual-Mode Endothelial-Mesenchymal Transformation of the Cardiac Valve. Proceedings of the …
[cited by applicant]
Balachandran K, Bakay M, Connolly JM, Zhang, X, Yoganathan AP, Levy RJ. Aortic Valve Cyclic Stretch Causes Increased Remodeling Activity and Enhanced Serotonin Receptor Responsiveness. Annals of Thoracic Surgery. Jul. 2…
[cited by applicant]
Ballen, K., “Targeting the stem cell niche: squeezing blood from bones,” (2007) Bone Marrow Transplantation 39:655-660.
[cited by applicant]
Ballen, K.K. et al., “Phase I trial of parathyroid hormone to facilitate stem cell mobilization,” Biology of Blood and Marrow Transplantation (2007) 13:838-843.
[cited by applicant]
Barros, S.P., et al., “Parathyroid hormone protects against periodontitis-associated bone loss,” J Dent Res. (2003) 82(10):791-5.
[cited by applicant]
Bauer, et al.: Structures of three polycystic kidney disease-like domains from Clostridium histolyticum collagenases CoIG and CoIH. Acta Crystallogr D Biol Crystallogr 2015;71:565-577.
[cited by applicant]
Bedi, B., et al., “Inhibition of antigen presentation and T cell costimulation blocks PTH-induced bone loss,” Ann N Y Acad Sci. (2010) 1192:215-21.
[cited by applicant]
Belinsky, G.S. et al., “Direct measurement of hormone-induced acidification in intact bone,” J Bone Miner Res., (2000) 15(3):550-6.
[cited by applicant]
Bellido, T., et al., “Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis,” Endocrinology (2005) 146(11):4577-83.…
[cited by applicant]
Bergenstock, M.K. et al., “Parathyroid hormone stimulation of noncanonical Wnt signaling in bone,” Ann N Y Acad Sci. (2007) 1116:354-9.
[cited by applicant]
Bergwitz, C. et al., “Rapid desensitization of parathyroid hormone dependent adenylate cyclase in perifused human osteosarcoma cells (SaOS-2),” Biochem Biophys Acta. (1994) 1222(3):447-56.
[cited by applicant]
Bianchi, E.N. et al., “Beta-arrestin2 regulates parathyroid hormone effects on a p38 MAPK and NFkappaB gene expression network in osteoblasts” Bone (2009) 45(4):716-25. Epub Jun. 26, 2009.
[cited by applicant]
Bilezikian, J.P. et al., “Asymptomatic primary hyperparathyroidism: new issues and new questions—bridging the past with the future,” J Bone Miner Res. (2002) 17(Suppl 2):N57-67.
[cited by applicant]
Bilezikian, J.P. et al., “Characterization and evaluation of asymptomatic primary hyperparathyroidism,” J Bone Miner Res. (1991) 6(Suppl 2):S85-9; discussion S121-4.
[cited by applicant]
Blachowicz, A. et al., “Serum 1-84 and 7-84 parathyroid hormone concentrations and bone in patients with primary hyperparathyroidism,” Langenbecks Arch Surg. (2008) 393(5):709-13. Epub Jul. 11, 2008.
[cited by applicant]
Blair, H. et al., “Recent advances in osteoclast biology and pathological bone resorption,” Histology and Histopathology (2004) 19(1):189-199.
[cited by applicant]
Broadus, A.E. et al., Humoral hypercalcemia of cancer. Identification of a novel parathyroid hormone-like peptide. N Engl J Med (1988) 319:556-563.
[cited by applicant]
Buargub, M.A. et al., “Prevalence and pattern of renal osteodystrophy in chronic hemodialysis patients: a cross sectional study of 103 patients,” Saudi J Kidney Dis Transpl. (2006) 17(3):401-7.
[cited by applicant]
Calvi, L.M. et al., “Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone,” J. Clin. Invest. (2001)107:277-286.
[cited by applicant]
Calvi, L.M. et al., “Osteoblastic cells regulate the haematopoietic stem cell niche,” Nature (2003) 425:841-846.
[cited by applicant]
Canalis, E. et al., “Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures,” J Clin Invest. (1989) 83(1):60-5.
[cited by applicant]
Canalis, E., “Effect of hormones and growth factors on alkaline phosphatase activity and collagen synthesis in cultured rat calvariae,” Metabolism (1983) 32(1): 14-20.
[cited by applicant]
Carter, P.H. et al., “Discovery of a small molecule antagonist of the parathyroid hormone receptor by using an N-terminal parathyroid hormone peptide probe,” Proc Natl Acad Sci U.S.A. (2007) 104(16):6846-6851.
[cited by applicant]
Carter, P.H. et al., “Selective and Nonselective Inverse Agonists for Constitutively Active Type-1 Parathyroid Hormone Receptors: Evidence for Altered Receptor Conformations,” Endocrinology (2001) 142(4):1534-1545.
[cited by applicant]
Caviness P, Bauer R, Tanaka K, Janowska K, Roeser JR, Harter D, Sanders J, Ruth C, Matsushita O, Sakon J. Ca<sup>2+</sup>-induced orientation of tandem collagen binding domains from clostridial collagenase CoIG permits …
[cited by applicant]
Chan, H.W. et al., “Prospective study on dialysis patients after total parathyroidectomy without autoimplant,” Nephrology (2009) 15(4):441-7.
[cited by applicant]
Chen, B. et al., “Homogeneous osteogenesis and bone regeneration by demineralized bone matrix loading with collagen-targeting bone morphogenetic protein-2,” Biomaterials (2007) 28:1027-1035.
[cited by applicant]
Chen, D. et al., “Bone morphogenetic proteins,” Growth Factors (2004) 22(4):233-241.
[cited by applicant]
Chen, Q. et al., “Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects…
[cited by applicant]
Cherian, P.P. et al., “Role of gap junction, hemichannels, and connexin 43 in mineralizing in response to intermittent and continuous application of parathyroid hormone,” Cell Commun Adhes. (2008) 15(1):43-54.
[cited by applicant]
Chevalley, T. et al., “Bone and hormones. Effects of parathyroid hormone on the bone,” Presse Med. (1999) 28(10):547-53.
[cited by applicant]
Choi, U.S., K.W. Leong, and H.S. Yoo, In vivo wound healing of diabetic ulcers using electrospun nanofibers immobilized with human epidermal growth factor (EGF). Biomaterials, 2008. 29(5): p. 587-96.
[cited by applicant]
Cleutjens, J.P., et al., Collagen remodeling after myocardial infarction in the rat heart. Am J Pathol, 1995. 147(2): p. 325-38.
[cited by applicant]
Cohen, A. et al., “Osteoporosis in adult survivors of adolescent cardiac transplantation may be related to hyperparathyroidism, mild renal insufficiency, and increased bone turnover,” J Heart Lung Transplant. (2005) 24(…
[cited by applicant]
Compston, J.E., “Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure,” Bone (2007) 40(6):1447-1452.
[cited by applicant]
Cormier, C., “Parathyroid hormone in osteoporosis,” Presse Med. (2006) 35(3 Pt 2):495-501.
[cited by applicant]
Corsi, A. et al., “Osteomalacic and hyperparathyroid changes in fibrous dysplasia of bone: core biopsy studies and clinical correlations,” J Bone Miner Res. (2003) 18(7):1235-46.
[cited by applicant]
Cosman, F., “Anabolic therapy for osteoporosis: parathyroid hormone,” Current Osteoporosis Reports (2005) 3(4):143-149.
[cited by applicant]
Cosman, F., “Parathyroid hormone treatment for osteoporosis,” Current Opinion in Endocrinology, Diabetes & Obesity (2008) 15:495-501.
[cited by applicant]
Cundy, T. et al., “Hyperparathyroid bone disease in chronic renal failure,” Ulster Med J. (1985) 54(Suppl):S34-43.
[cited by applicant]
Datta, N.S. et al., “Distinct roles for mitogen-activated protein kinase phosphatase-1 (MKP-1) and ERK-MAPK in PTH1R signaling during osteoblast proliferation and differentiation,” Cell (2010) 22(3):457-66. Epub.
[cited by applicant]
Hoare, S.R. et al., “Specificity and stability of a new PTH1 receptor antagonist, mouse TIP(7-39),” Peptides (2002) 23(5):989-998.
[cited by applicant]
Hock, J.M. et al., “Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone,” J Bone Miner Res. (1992) 7(1):65-72.
[cited by applicant]
Hock, J.M. et al., “Human parathyroid hormone-(1-34) increases bone mass in ovariectomized and orchidectomized rats,” Endocrinology (1988) 122(6):2899-2904.
[cited by applicant]
Holick, M.F. et al., “Topical PTH (1-34) is a novel, safe and effective treatment for psoriasis: a randomized self- controlled trial and an open trial,” (2003) British J. Dermatology 149:370-376.
[cited by applicant]
Homme, M. et al., “Differential regulation of RGS-2 by constant and oscillating PTH concentrations,” Calcif Tissue Int. (2009) 84(4):305-12. Epub Feb. 20, 2009.
[cited by applicant]
Horwitz, M.J. et al., “Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D,” J Bone Miner Res. (2005) 20(10):1792-803. Epub Jun. 6, 2005.
[cited by applicant]
Horwitz, M.J. et al., “Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose,” J Clin Endocrinol Metab. (2010) 95(3):1279-87.
[cited by applicant]
Hruska, K.A. et al., “Regulation of skeletal remodeling by parathyroid hormone,” Contrib Nephrol. (1991) 91:38-42.
[cited by applicant]
Huang, Z., et al., Uncoupling the Mitogenic and Metabolic Functions of FGF1 by Tuning FGF1-FGF Receptor Dimer Stability. Cell Rep, 2017. 20(7): p. 1717-1728.
[cited by applicant]
Hui, Q., et al., FGF Family: From Drug Development to Clinical Application. Int J Mol Sci, 2018. 19(7).
[cited by applicant]
Hunter, G.K. et al., “Induction of collagen mineralization by a bone sialoprotein-decorin chimeric protein,” J. Biomed. Mater. Res. (2001) 55(4):496-502.
[cited by applicant]
Ichikawa, S., et al., High dietary phosphate intake induces development of ectopic calcifications in a murine model of familial tumoral calcinosis. J Bone Miner Res, 2014. 29(9): p. 2017-23.
[cited by applicant]
Iida-Klein, A. et al., “Short-term continuous infusion of human parathyroid hormone 1-34 fragment is catabolic with decreased trabecular connectivity density accompanied by hypercalcemia in C57BL/J6 mice,” J Endocrinol.…
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority for Application No. PCT/US08/004589 dated Oct. 28, 2008 (17 pages).
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority for Application No. PCT/ US12/69831 dated Mar. 14, 2013 (12 pages).
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority for Application No. PCT/ US2013/25541 dated Jun. 17, 2013 (16 pages).
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority for Application No. PCT/ US2018/017665 dated May 7, 2018 (11 pages).
[cited by applicant]
Ishii, H. et al., “Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia,” Bone (2000) 26(2):175-82.
[cited by applicant]
Ishikawa, T. et al., “Delivery of a growth factor fusion protein having collagen-binding activity to wound tissues,” Artif. Organs (2003) 27(2):147-154.
[cited by applicant]
Ishikawa, T. et al., “Establishment of a functionally active collagen-binding vascular endothelial growth factor fusion protein in situ,” Arterioscler. Thromb. Vasc. Biol. (Sep. 2006):1-7.
[cited by applicant]
Ishikawa, T. et al., “Production of a biologically active epidermal growth factor fusion protein with high collagen affinity,” J. Biochem. (2001) 129(4)627-633.
[cited by applicant]
Ishizuya, T. et al., “Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells,” J Clin Invest. (1997) 99(12):2961-70.
[cited by applicant]
Ito, M., “Parathyroid and bone: Effect of parathyroid hormone on bone quality,” Clin Calcium. (2007) 17(12):1858-64.
[cited by applicant]
Ito, M., “Parathyroid hormone and bone quality,” Clin Calcium. (2005) 15(12):31-7.
[cited by applicant]
Jeon, E. et al., “Engineering and application of collagen-binding fibroblast growth factor 2 for sustained release,” (2013) J. of Biomed. Materials Research: Part A.
[cited by applicant]
Jilka, R.L. et al., “Continuous elevation of PTH increases the number of osteoblasts via both osteoclast-dependent and -independent mechanisms,” J Bone Miner Res. (2010) 25(11):2427-37.
[cited by applicant]
Jilka, R.L., “Molecular and cellular mechanisms of the anabolic effect of intermittent PTH,” Bone (2007) 40(6):1434-1446. Epub Apr. 6, 2007.
[cited by applicant]
Jonsson, K.B. et al., “Tuberoinfundibular peptide 39 binds to the parathyroid hormone (PTH)/PTH-related peptide receptor, but functions as an antagonist,” Endocrinology (2001) 142(2):704-709.
[cited by applicant]
Kaji, H., “Parathyroid and bone: Effects of parathyroid hormone on bone resorption and formation: differences between intermittent and continuous treatment,” Clin Calcium., (2007) 17(12):1836-42.
[cited by applicant]
Katikaneni et al., “Therapy for alopecia areata in mice using parathyroid hormone agonists and antagonists, linked to a collagen-binding domain,” J. of Investigative Dermatology Symposium Proceedings, (2013) 16(1):S61-S…
[cited by applicant]
Katikaneni et al., “Treatment for chemotherapy-induced alopecia in mice using parathyroid hormone agonists and antagonists linked to coolagen binding domain,” Int. J. Cancer (2012) 131(5):E813-821.
[cited by applicant]
Katikaneni R., et al. Parathyroid hormone linked to a collagen binding domain (PTH-CBD) promotes hair growth in a mouse model of chemotherapy-induced alopecia in a dose-dependent manner. Anticancer Drugs. 2014. 25(7):81…
[cited by applicant]
Katikaneni, R. et al. Therapy for alopecia Areata in Mice by Stimulating the Hair Cycle with Parathyroid Hormone Agonists Linked to a Collagen-Binding Domain. The Journal of Investigative Dermatology Symposium. 2015. 17…
[cited by applicant]
Katikaneni, R. et al. Treatment and Prevention of Chemotherapy-induced alopecia with PTH-CBD, a collagen targeted parathyroid hormone analog, in a non-depilated mouse model. Anticancer Drugs. 2014. 25(1): 30-38.
[cited by applicant]
Kato T, et al: Single local injection of recombinant fibroblast growth factor-2 stimulates healing of segmental bone defects in rabbits. J Orthop Res 1998;16:654-659.
[cited by applicant]
Kawaguchi H, et al: A local application of recombinant human fibroblast growth factor 2 for tibial shaft fractures: A randomized, placebo-controlled trial. J Bone Miner Res 2010;25:2735-2743.
[cited by applicant]
Kawaguchi H, et al: Local application of recombinant human fibroblast growth factor-2 on bone repair: a dose-escalation prospective trial on patients with osteotomy. J Orthop Res 2007;25:480-487.
[cited by applicant]
Kawaguchi H, et al: Stimulation of fracture repair by recombinant human basic fibroblast growth factor in normal and streptozotocin-diabetic rats. Endocrinology 1994;135:774-781.
[cited by applicant]
Kaye, M. et al., “Elective total parathyroidectomy without autotransplant in end-stage renal disease,” Kidney Int. (1989) 35(6):1390-9.
[cited by applicant]
Kerr, R., S. Agrawal, S. Maity, B. Koppulu, S. Jayanthi, G. S. Kumar, R. K. Gundampati, D. S. McNabb, D. A. Zaharoff, and S. K. Thallapuranam (2019) Design of thrombin resistant acidic human fibroblast growth factor (hF…
[cited by applicant]
Khan, A. et al., “Primary hyperparathyroidism: pathophysiology and impact on bone,” Cmaj. (2000) 163(2):184-7.
[cited by applicant]
Kido, S. et al., “Mechanism of PTH actions on bone,” Clin Calcium. (2003) 13(1):14-8.
[cited by applicant]
Kistler, H., “Primary hyperparathyroidism: An analysis of 152 patients with special references to acute life threatening complications (acute hyperparathyroidism),” Schweiz Med Wochenschr. (1976) 106(Suppl 3):1-61.
[cited by applicant]
Kitazawa, R. et al., “Effects of continuous infusion of parathyroid hormone and parathyroid hormone-related peptide on rat bone in vivo: comparative study by histomorphometry,” Bone Miner. (1991) 12(3):157-66.
[cited by applicant]
Klempa, I., “Treatment of secondary and tertiary hyperparathyroidism—surgical viewpoints,” Chirurg. (1999) 70(10):1089-101.
[cited by applicant]
Koh, A.J. et al., “3′,5′-Cyclic adenosine monophosphate activation in osteoblastic cells: effects on parathyroid hormone-1 receptors and osteoblastic differentiation in vitro,” Endocrinology (1999) 140(7):3154-62.
[cited by applicant]
Komarova, S.V., “Mathematical model of paracrine interactions between osteoclasts and osteoblasts predicts anabolic action of parathyroid hormone on bone,” Endocrinology. (2005) 146(8):3589-95. Epub Apr. 28, 2005.
[cited by applicant]
Kousteni, S. et al., “The cell biology of parathyroid hormone in osteoblasts,” Curr Osteoporos. Rep. (2008) 6(2):72-6.
[cited by applicant]
Kroll, M.H., “Parathyroid hormone temporal effects on bone formation and resorption,” Bull Math Biol. (2000) 62(1):163-88.
[cited by applicant]
Kubler, N.R. et al., “Inductive properties of recombinant human BMP-2 produced in a bacterial expression system,” Int. J. Oral Maxillofac. Surg. (1998) 27:305-309.
[cited by applicant]
Wan, Q. et al., “Intra-articular injection of parathyroid hormone in the temporomandibular joint as a novel therapy for mandibular asymmetry,” Med Hypotheses (2009) 74(4):685-7.
[cited by applicant]
Wang, C.A. et al., “Natural history of parathyroid carcinoma. Diagnosis, treatment, and results,” Am J Surg. (1985) 149(4):522-7.
[cited by applicant]
Wang, E. et al., “Recombinant human bone morphogenetic protein induces bone formation,” Proc. Natl. Acad. Sci. USA (1990) 87:2220-2224.
[cited by applicant]
Wang, Y. et al., “A theoretical model for simulating effect of parathyroid hormone on bone metabolism at cellular level,” Mol Cell Biomech. (2009) 6(2):101-12.
[cited by applicant]
Wang, Y. et al., “Gender differences in the response of CD-1 mouse bone to parathyroid hormone: potential role of IGF-I,” J Endocrinol. (2006) 189(2):279-87.
[cited by applicant]
Watanabe-Nakayama, T., et al (2016). “High-speed atomic force microscopy reveals strongly polarized movement of clostridial collagenase along collagen fibrils.” Sci Rep 6: 28975.
[cited by applicant]
Watson, P.H. et al., “Enhanced osteoblast development after continuous infusion of hPTH(1-84) in the rat,” Bone (1999) 24(2):89-94.
[cited by applicant]
Weber, M., et al., Blood-Contacting Biomaterials: In Vitro Evaluation of the Hemocompatibility. Front Bioeng Biotechnol, 2018. 6: p. 99.
[cited by applicant]
Weir, E.C. et al., “Synthetic parathyroid hormone-like protein (1-74) is anabolic for bone in vivo,” Calcif Tissue Int. (1992) 51(1):30-4.
[cited by applicant]
Wesche, J., J. Malecki, A. Wiedlocha, C. S. Skjerpen, P. Claus and S. Olsnes (2006). “FGF-1 and FGF-2 require the cytosolic chaperone Hsp90 for translocation into the cytosol and the cell nucleus.” J Biol Chem 281(16): …
[cited by applicant]
Whitfield, J.F., “Taming Psoriatic Keratinocytes-PTHs' uses go up another notch,” J. Cell. Biochem. (2004) 93:251-256.
[cited by applicant]
Wilson, J.J. et al., “A bacterial collagen-binding domain with novel calcium-binding motif controls domain orientation,” EMBO Journal (2003) 22(8)1743-1752.
[cited by applicant]
Wuthrich, R.P. et al., “The role of calcimimetrics in the treatment of hyperparathyroidism,” Eur. J. Clin. Invest. (2007) 37(12):915-922.
[cited by applicant]
Xu, M. et al., “Basal bone phenotype and increased anabolic responses to intermittent parathyroid hormone in healthy male COX-2 knockout mice,” Bone (2010) 47(2):341-52. Epub May 13, 2010.
[cited by applicant]
Yang, C. et al., “Effects of continuous and pulsatile PTH treatments on rat bone marrow stromal cells,” Biochem Biophys Res Commun. (2009) 380(4):791-6. Epub Feb. 3, 2009.
[cited by applicant]
Yoshihara, K. et al., “Cloning and nucleotide sequence analysis of the colH gene from Clostridium histolyticum encoding a collagenase and a gelatinase,” J Bacteriol (1994) 176:6489-6496.
[cited by applicant]
Younes, N.A. et al., “Laboratory screening for hyperparathyroidism,” Clin Chim Acta. (2005) 353(1-2):1-12.
[cited by applicant]
Zakrzewska, M., D. Krowarsch, A. Wiedlocha, S. Olsnes and J. Otlewski (2006). “Structural requirements of FGF-1 for receptor binding and translocation into cells.” Biochemistry 45(51): 15338-15348.
[cited by applicant]
Zang, X.Y. et al., “Effects of parathyroid hormone and estradiol on proliferation and function of human osteoblasts from fetal long bone: An in vitro study,” Chin Med J (Engl). (1994) 107(8):600-3.
[cited by applicant]
Zaruba, M.M. et al., “Parathyroid hormone treatment after myocardial infarction promotes cardiac repair by enhanced neovascularization and cell survival,” Cardiovasc Res (2008) 77(4):722-731.
[cited by applicant]
Zhou, H. et al., “Anabolic action of parathyroid hormone on cortical and cancellous bone differs between axial and appendicular skeletal sites in mice,” Bone (2003) 32(5):513-520.
[cited by applicant]
Swencki-Underwood, B. et al., “Expression and characterization of a human BMP-7 variant with improved biochemical properties,” Protein Expr. Purif. (2008) 57(2): 312-319.
[cited by applicant]
An, B., et al.(2015). “Collagen interactions: Drug design and delivery.” Adv Drug Deliv Rev. Feb. 1, 2016:97:69-84. Epub Nov. 26, 2015.
[cited by applicant]
Duijvelshoff, R., et al., Host Response and Neo-Tissue Development during Resorption of a Fast Degrading Supramolecular Electrospun Arterial Scaffold. Bioengineering (Basel), 2018. 5(3).
[cited by applicant]
Dunn, L., et al., Murine model of wound healing. J Vis Exp, 2013(75): p. e50265.
[cited by applicant]
Fields, G. B. (2013). “Interstitial collagen catabolism” J Biol Chem 288(13): 8785-8793.
[cited by applicant]
Galiano, R.D., et al., Quantitative and reproducible murine model of excisional wound healing. Wound Repair Regen, 2004. 12(4): p. 485-92.
[cited by applicant]
Gao, F., A.D. Kight, Ad, R. Henderson, S. Jayanthi, P. Patel, M. Murchison, R. L. Goforth, S. K. Thallapuranam, R. L. Henry, and C. D. Heyes (2015). Regulation of Structural Dynamics within a Signal Recognition Particle…
[cited by applicant]
Gho, J., et al., Heart failure following STEMI: a contemporary cohort study of incidence and prognostic factors. Open Heart, 2017. 4(2): p. e000551.
[cited by applicant]
Irwin D, Shin DH, Zhang S, Barr BK, Sakon J, Karplus PA, Wilson DB. Roles of the catalytic domain and two cellulose binding domains of Thermomonospora fusca E4 in cellulose hydrolysis. J Bacteriol. Apr. 1998;180(7):1709…
[cited by applicant]
Jansen, P.L. et al., “Hernia disease and collagen gene regulation: are there clues for intervention?” Hernia (2006) 10:486-491.
[cited by applicant]
Khan SN, et al.: Bone growth factors. Orthop Clin North Am 2000;31:375-388.
[cited by applicant]
Kuwaba, K., et al.(2001). “Elongated dermatan sulphate in post-inflammatory healing skin distributes among collagen fibrils separated by enlarged interfibrillar gaps.” Biochem J 358(Pt 1): 157-163.
[cited by applicant]
Lam NT, Lam H, Sturdivant NM, Balachandran K. Fabrication of a matrigel-collagen semi-interpenetrating scaffold for use in dynamic valve interstitial cell culture. Biomedical Materials. 2017. 12(4):045013.
[cited by applicant]
Lam NT, Muldoon TJ, Quinn KP, Rajaram N, Balachandran K. Valve interstitial cell contractile strength and metabolic state are dependent on its shape. Integrative Biology (Cambridge). 2016;8(10):1079-1089).
[cited by applicant]
“Liang, C.C., A.Y. Park, and J.L. Guan, In vitro scratch assay: a convenient andinexpensive method for analysis of cell migration in vitro. Nat Protoc, 2007. 2(2): p. 329-33.”.
[cited by applicant]
Lu JZ, Fujiwara T, Komatsuzawa H, Sugai M, Sakon J. Cell wall-targeting domain of glycylglycine endopeptidase distinguishes among peptidoglycan cross-bridges. J Biol Chem. Jan. 6, 2006;281(1):549-58. PubMed PMID: 162579…
[cited by applicant]
Malyszko, J. et al., “Markers of bone metabolism in hemodialyses and hemodiafiltration,” Ren. Fail. (2007) 29(5):595-601.
[cited by applicant]
Miyachi, Y. et al., “Long-term safety and efficacy of high-concentration (20 mug/g) tacalcitol ointment in psoriasis vulgaris,” Eur J Dermatol (2002) 12(5):463-468.
[cited by applicant]
Perez J, Diaz N, Tandon I, Plate R, Martindale C, Balachandran K. Elevated serotonin interacts with angiotensin-II to result in altered valve interstitial cell contractility and remodeling. Cardiovascular Engineering an…
[cited by applicant]
Proesmans, W. & Van Dyck, M. “Enalapril in children with Alport syndrome” Pediatr Nephrol (2004) 19:271-275.
[cited by applicant]
Ruppert, R. et al., “Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity,” Eur. J. Biochem. (1996) 237:295-302.
[cited by applicant]
Schneider, A. et al., “Skeletal homeostasis in tissue-engineered bone,” J Orthop Res. (2003) 21(5):859-64.
[cited by applicant]
Spurney, R.F. et al., “Anabolic effects of a G protein-coupled receptor kinase inhibitor expressed in osteoblasts,” J Clin Invest. (2002) 109(10):1361-71.
[cited by applicant]
Lam NT, Tandon I, Balachandran K. The role of fibroblast growth factor 1 and 2 on the pathological behavior of valve interstitial cells in a three-dimensional mechanically-conditioned model. Journal of Biological Engine…
[cited by applicant]
Lane, J.M., “Bone morphogenic protein science and studies,” J. Orthop. Trauma (2005) 19(10 Supp.):S17-22.
[cited by applicant]
Lemaire, V. et al., “Modeling the interactions between osteoblast and osteoclast activities in bone remodeling,” J Theor Biol. (2004) 229(3):293-309.
[cited by applicant]
Li, X. et al., “Determination of dual effects of parathyroid hormone on skeletal gene expression in vivo by microarray and network analysis,” J Biol Chem. (2007) 282(45):33086-97. Epub Aug. 9, 2007.
[cited by applicant]
Li, X. et al., “In vivo parathyroid hormone treatments and RNA isolation and analysis,” Methods Mol Biol. (2008) 455:79-87.
[cited by applicant]
Liu, J. et al., “Intermittent PTH administration: a novel therapy method for periodontitis-associated alveolar bone loss,” Med Hypotheses. (2009) 72(3):294-6. Epub Nov. 30, 2008.
[cited by applicant]
Locklin, R.M. et al., “Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone,” J Cell Biochem. (2003) 89(1):180-90.
[cited by applicant]
Locus BAA06251 (GI 710023), Collagenase precursor from Clostridium histolyticum, Jan. 30, 2003. This amino acid sequence is disclosed in this application as Seq ID No. 6. The sequence of residues 901-1021 of BAA06251 co…
[cited by applicant]
Locus EAW68494 (GI 119588900), Parathyroid hormone isoform from
[cited by applicant]
Lotinun, S. et al., “Differential effects of intermittent and continuous administration of parathyroid hormone on bone histomorphometry and gene expression,” Endocrine. (2002) 17(1):29-36.
[cited by applicant]
Lotinun, S. et al., “Triazolopyrimidine (trapidil), a platelet-derived growth factor antagonist, inhibits parathyroid bone disease in an animal model for chronic hyperparathyroidism,” Endocrinology. (2003) 144(5):2000-7.
[cited by applicant]
Lumachi, F. et al., “Lumbar spine bone mineral density changes in patients with primary hyperparathyroidism according to age and gender,” Ann N Y Acad Sci. (2007) 1117:362-6. Epub Jul. 26, 2007.
[cited by applicant]
Ma, Y.L. et al., “Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation,” Endocrinology (2001) 1…
[cited by applicant]
Machado Do Reis, L. et al., “Accentuated osteoclastic response to parathyroid hormone undermines bone mass acquisition in osteonectin-null mice,” Bone (2008) 43(2):264-73. Epub Apr. 13, 2008.
[cited by applicant]
Malluche, H.H. et al., “Effects of long-term infusion of physiologic doses of 1-34 PTH on bone” Am J Physiol. (1982) 242(2):F197-201.
[cited by applicant]
Malluche, H.H. et al., “Endogenous calcitonin does not protect against hyperparathyroid bone disease in renal failure,” Miner. Electrolyte Metab. (1986) 12(2):113-8.
[cited by applicant]
Malluche, H.H. et al., “Influence of the parathyroid glands on bone metabolism,” Eur J Clin Invest. (2006) 36(Suppl 2):23-33.
[cited by applicant]
Malluche, H.H. et al., “Osteomalacia and hyperparathyroid bone disease in patients with nephrotic syndrome,” J Clin Invest. (1979) 63(3):494-500.
[cited by applicant]
Marcinkowska, E., K. Superat and A. Wiedlocha (2006). “FGF-1 as a possible carrier for targeted drug delivery.” Oncol Res 16(1): 27-34.
[cited by applicant]